AU2007243181A1 - Composition and methods for the detection of Cripto-3 - Google Patents

Composition and methods for the detection of Cripto-3 Download PDF

Info

Publication number
AU2007243181A1
AU2007243181A1 AU2007243181A AU2007243181A AU2007243181A1 AU 2007243181 A1 AU2007243181 A1 AU 2007243181A1 AU 2007243181 A AU2007243181 A AU 2007243181A AU 2007243181 A AU2007243181 A AU 2007243181A AU 2007243181 A1 AU2007243181 A1 AU 2007243181A1
Authority
AU
Australia
Prior art keywords
tdgf3
polynucleotide
cripto
sample
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007243181A
Other languages
English (en)
Inventor
John Carulli
Eugene Choi
Olivia Orozco
Michele Sanicola-Nadel
Chao Sun
Suzanne Szak
Rich Tizard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Publication of AU2007243181A1 publication Critical patent/AU2007243181A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2007243181A 2006-04-28 2007-04-30 Composition and methods for the detection of Cripto-3 Abandoned AU2007243181A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79580706P 2006-04-28 2006-04-28
US60/795,807 2006-04-28
PCT/US2007/010399 WO2007127461A2 (en) 2006-04-28 2007-04-30 Composition and methods for the detection of cripto-3

Publications (1)

Publication Number Publication Date
AU2007243181A1 true AU2007243181A1 (en) 2007-11-08

Family

ID=38656259

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007243181A Abandoned AU2007243181A1 (en) 2006-04-28 2007-04-30 Composition and methods for the detection of Cripto-3

Country Status (7)

Country Link
US (1) US20100041032A1 (enExample)
EP (1) EP2021510A2 (enExample)
JP (1) JP2009535033A (enExample)
CN (1) CN101479391A (enExample)
AU (1) AU2007243181A1 (enExample)
CA (1) CA2650379A1 (enExample)
WO (1) WO2007127461A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20033208A3 (en) * 2001-04-26 2004-03-17 Biogen, Inc. Cripto blocking antibodies and uses thereof
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
CA2593212A1 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5264557A (en) * 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
NZ525380A (en) * 2000-09-18 2008-06-30 Biogen Idec Inc Non-fucosylated forms of Cripto and their use as tumor blocking agents
EP1494693B1 (en) * 2002-03-22 2010-12-08 Biogen Idec MA Inc. Cripto-specific antibodies

Also Published As

Publication number Publication date
CA2650379A1 (en) 2007-11-08
WO2007127461A3 (en) 2008-06-26
JP2009535033A (ja) 2009-10-01
EP2021510A2 (en) 2009-02-11
US20100041032A1 (en) 2010-02-18
CN101479391A (zh) 2009-07-08
WO2007127461A2 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
KR101828290B1 (ko) 자궁내막암 마커
Pflueger et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer
EP1994410B1 (en) Methods for early detection of cancer
US20100105051A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP5937017B2 (ja) Ａｌｋ阻害剤に対する自然耐性または獲得耐性を有する癌の同定、評価および治療法
US20100291616A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
CA2428112A1 (en) Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
CA2807104C (en) Bard1 isoforms in lung and colorectal cancer and use thereof
CA2504903A1 (en) Method for identifying risk of melanoma and treatments thereof
CA2687997A1 (en) Diagnostic methods and markers
US11015224B2 (en) RAF gene fusions
EP2148932B1 (en) Sox11 expression in malignant lymphomas
US20100041032A1 (en) Composition and methods for the detection of cripto-3
US7807790B2 (en) Peptide sequence that promotes tumor invasion
US20060122132A1 (en) Use of murine genomic regions identified to be involved in tumor developement for the development of anti-cancer drugs and diagnosis of cancer
US7883896B2 (en) Marker molecules associated with lung tumors
EP2460892A2 (en) Method and kit for prognosis mantle cell lymphoma
WO2015194524A1 (ja) Ｂ前駆細胞性急性リンパ芽球性白血病新規キメラ遺伝子
KR101683961B1 (ko) 방광암 재발 진단 마커
US7745121B2 (en) Polymorphism in the macrophage migration inhibitory factor (MIF) gene as marker for prostate cancer

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application